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Background: The Glivec International Patient Assistance Program (GIPAP) is a unique direct-to-patient pro-
gram that provides imatinib (Glivec) at no cost to eligible patients in low- and middle-income countries
(LMICs) with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumor (GIST). This paper anal-
yses the output, outcome and impact of the program between 2001 and 2014 using the data collected by the
Max Foundation.
Method:We extracted data on GIPAP patients’ country of residence, sex, diagnosis, date of enrollment in GIPAP,
age at enrollment, case closure date, and reason for closure from The Max Foundation database covering the
period 2001 to 2014. We used Kaplan-Meier method to assess the survival rate of patients in GIPAP and used
the proportional hazard regressionmodel to estimate the effect of different variables on patients’ survival.
Findings: About 63,000 GIPAP patients in 93 countries received over 71 million defined daily doses (DDD) of
imatinib between 2001 and 2014. Our analysis showed that GIPAP patients had a 5-year survival rate of 89%
which compares favorably to survival in high income countries despite the challenges of delivering cancer
care in LMICs. Age at enrollment into the program, sex, duration between diagnosis and enrollment into pro-
gram, year of enrollment, and patients’ diagnosis (CML vs non-CML) were factors that influenced survival.
Interpretation: The GIPAP program has improved the survival of CML and GIST patients in LMICs, most of whom
would not have had access to imatinib in the absence of the donation and therapeutic support of the program.
Funding: This work was funded as part of Access Accelerated case studies. Access Accelerated is an initiative
of more than 20 global biopharmaceutical companies in partnership with the World Bank and Union of Inter-
national Cancer Control that seeks to reduce barriers to prevention, treatment and care for non-communica-
ble diseases in LMICs.
© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Chronic myeloid leukemia (CML) is a rare hematologic malignancy
that globally affects between one and two per 100,000 people annu-
ally [1,2]. CML had a poor prognosis and a median survival of less
than 5 years before 2001, but is now considered a chronic disease
since the advent of targeted therapies such as imatinib (Glivec)
[1,35]. With the introduction of imatinib, five-year cumulative rela-
tive survival ratios of CML in Swedish patients younger than 79 yearsincreased from 0.54 between 1994 and 2000 to 0.80 between 2001
and 2008 [6]. Similarly, the five-year survival rate of CML increased
from 63% with interferon therapy to 88% with the introduction of
imatinib in a cancer treatment center in the United States [7]. Fur-
thermore, imatinib has fewer side effects compared with alternative
treatments [3,8].
Despite the improved outcomes for CML patients that have been
treated with imatinib, the average monthly cost of $2500$3500
USD in high income countries could limit its use in low- and middle-
income countries (LMICs) [9]. This led Novartis in 2001 to establish
the Glivec International Patient Assistance Program (GIPAP) to assist
patients in LMICs not able to afford treatment [1,9].
Research in Context
Evidence before this study
Glivec International Patient Assistance Program (GIPAP) has the
largest database of chronic myeloid leukemia patients receiving
imatinib in low- and middle-income countries (LMICs). Previous
studies using the GIPAP data have examined institutional factors
related to patient enrollment and outcomes, regional variations in
age at diagnosis, and three-year survival rates of GIPAP patients.
However, none of the studies has examined the medium- to long-
term (five to seven years) survival of GIPAP patients nor estimated
the number of lives saved through the program.
Added value of this study
This paper examines the medium- to long-term survival of
GIPAP patients and estimates the number of lives saved through
the program using routinely collected GIPAP program data.
Implications of all the available evidence
The short (one year) and medium- to long-term (five to seven
years) impact of GIPAP program on survival of CML patients is
excellent, and unadjusted for patients’ prognosis at time of
diagnosis, compares favorably to survival in high-income coun-
tries, despite the challenges of delivering cancer care in LMICs.
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global program that was established by Novartis Pharma AG in 2001
and implemented in partnership with The Max Foundation and Axios
International, to provide imatinib (Glivec) at no cost to eligible
patients with CML or gastrointestinal stromal tumor (GIST) [1,10]. Eli-
gible patients include Philadelphia chromosome-positive CML or c-
kit (CD117) positive GIST patients who were not insured, not reim-
bursed, or could not pay for the treatment privately and were in
countries that have minimal reimbursement capabilities and where
regulatory approval or at least an import license for Glivec for CML/
GIST had been obtained [1113].
Using a direct-to-patient approach, GIPAP involves different levels
of partners  patients, patients’ physicians, implementing partners,
and Novartis. Each of the partners plays specific roles that ensure the
success of the program. Novartis identified the countries where the
programs would be implemented and collaborated with The Max
Foundation to select qualified institutions and physicians in these
countries. It also supplied the requested amount of imatinib to the
cancer treating institutions and contracted with Axios International
to deal with supply logistics in countries where the company lacked
the necessary logistics in-country to support drug importation [1].
The Max Foundation conducted socioeconomic evaluation and
verified the eligibility of patients, in addition to requesting product
donation delivery from Novartis at three-month intervals based on
individual patient’s physician prescription. The Max Foundation also
supported patients’ adherence to medications by providing peer-to-
peer support and supported by Novartis and others, also engaged in
CML educational initiatives and awareness campaigns [1,2]. Addition-
ally, The Max Foundation and Axios International maintained data-
bases of data from different patients and institutions involved in the
program [9]. Axios International apart from managing the drug
import process in some countries, supported interaction with GIPAP
physicians and institutions in countries where Novartis did not have
a presence to ensure that they followed correct procedures [13,14].
The physicians in GIPAP institutions diagnosed the patients and
made a request to The Max Foundation for the patients to be enrolled
in the program. There were no limits to the number of patientseligible for GIPAP in any participating institution or country. Partici-
pation of physicians was voluntary, but they played an important
role in the success of the program [1,2]. The patients’ physicians
worked with the implementing partners to ensure that the patients
received the appropriate doses they needed at the appropriate time.
The physicians were also responsible for managing and reviewing
enrolled patients quarterly. If a patient did not come for the quarterly
review and attempts by The Max Foundation to locate the patient
failed, such a case was considered as "closed" or non-active, and
could be re-instated into the program if contact was re-established
[2]. In addition, the physicians and nurses had to comply with the
demanding data entry needs of the program by filling out reports for
each patient quarterly that were collected and validated by The Max
Foundation [1,2]. To ensure adherence to the medication, which has
been shown to correlate with improved survival, the physicians also
contacted patients with appointment reminders and other necessary
information [1].
Previous studies using the GIPAP data have examined institutional
factors related to patient enrollment and outcomes [9], regional var-
iations in age at diagnosis and survival of GIPAP patients [15], and
three-year survival rates of GIPAP patients [2,15]. However, none of
the studies has examined the medium- to long-term survival of
GIPAP patients nor estimated the number of lives saved through the
program.
This paper examines the medium- to long-term survival of GIPAP
patients and estimates the number of lives saved through the pro-
gram using routinely collected GIPAP program data. This paper also
reports the outputs and outcomes of the GIPAP program using the
Boston University Access to Medicines Metrics Framework developed
as part of the Access Accelerated initiative [16,17]. The Boston Uni-
versity Access to Medicines Metrics Framework consists of a taxon-
omy of 11 global health program strategies such as medicine
donation and price schemes, with the corresponding logic models
designed to report inputs, activities, outputs, outcomes, and impacts
of pharmaceutical industry led global health programs [16].2. Methods
2.1. Data sources
We extracted data on patients’ country of residence, sex, diagno-
sis, date of enrollment in GIPAP, age at enrollment, case closure date,
and reason for closure from The Max Foundation database covering
the period 2001 to the end of 2014. The analysis included data from
93 countries that were involved in GIPAP between 2001 and 2014.
This also includes patients enrolled in the Novartis Oncology Access
(NOA) program in India who were receiving free imatinib, referred to
as NOA-GIPAP patients. However, for the purposes of this paper, we
will collectively refer to both the GIPAP and NOA-GIPAP patients as
GIPAP patients.2.2. Variables
We calculated the total daily doses of imatinib donated to GIPAP
patients by Novartis by dividing the total volume of medicine
donated in milligrams by the defined daily dose (DDD) of imatinib.
Since no DDD for imatinib has been established by the World Health
Organization [18], we used a DDD of 400 mg which is the modal daily
dose of imatinib taken by GIPAP patients.
Total daily doses of imatinib donated ¼ Volume of imatinib donated in
milligrams=defined daily dose of imatinib
The potential number of CML patients saved by GIPAP in five years
was calculated by subtracting the estimated number that survived
Table 1








Others (e.g. Ph positive ALL; systemic
mastocytosis)
517 0.81%
Stage of CML disease
Chronic 46,752 86.78%
Accelerated 4522 8.39%
Blast Crisis 2601 4.83%
Mean Standard deviation
Age at diagnosis (years) 40.57 15.39
Age at enrollment into GIPAP (years) 41.47 15.40
Time between diagnosis and enrollment
in GIPAP (months)
10.33 23.83
Duration of patient follow up (months) 40.74 34.70
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absence of imatinib [7].
Potential number of CML patients saved by GIPAP in 5 years ¼ Estimated
number that survived after 5 yearsNumber expected to survive
after 5 years in the absence of imatinib:
2.3. Statistical analysis
We did descriptive statistics using sums, means and standard
deviations for continuous variables and percentages for categorical
variables. We used Kaplan-Meier method to assess the survival rate
of patients in GIPAP. Our event of interest was death of patient, while
closure due to other reasons such as loss to follow-up, and patients
that were still alive at the end of 2014, were analyzed as censored
data. Additionally, we conducted a sensitivity analysis with the
assumption that patients that were lost to follow-up had all died at
the point they were lost to follow-up. We also systematically con-
ducted sensitivity analyses without data from India and China (both
countries contributed about 50% of GIPAP patients), to see if different
results would be obtained. We used Wilcoxon and Log-Rank tests to
assess whether short- (one year) or long-term differences (five to
seven years) exist in survival between patients with CML diagnosis
and those with non-CML (mostly gastrointestinal stromal tumor)
diagnosis, and between males and females. Furthermore, we used a
proportional hazard regression model to estimate the effect of sex,
diagnosis (CML vs non-CML), age at enrollment in GIPAP, time in
months from diagnosis to enrollment in GIPAP, and year of enroll-
ment, on patients’ survival.
The estimated number of GIPAP CML patients that survived after
five years was calculated by multiplying the five-year survival rate in
GIPAP CML patients by the number of patients enrolled in the pro-
gram. The number expected to survive after five years in the absence
of imatinib was calculated by multiplying the 19821997 five-year
survival rate of 650 CML patients receiving treatment in a cancer
treatment center in the United States (63%) by the number of people
enrolled in the program [7]. The 19821997 five-year survival rate
was used to calculate the expected number of patients that would
have survived in the absence of imatinb because it was one of the
most recent published five-year survival rate of CML prior to the
approval of imatinib in 2001 [7]. The graph of patients enrolled in
GIPAP was performed using Microsoft Excel and SAS 9.4 software
package (SAS Institute Inc., Cary, NC, USA) was used for all other sta-
tistical analysis.
2.4. Role of the funding source
The study sponsor had no role in the study design; collection,
analysis, and interpretation of data; in the writing of the manuscript;
and in the decision to submit the paper for publication. The authors
had full access to all the data in the study and had final responsibility
for the decision to submit for publication.
2.5. Data statement
The dataset analyzed for this publication is available on request.
3. Results
3.1. Descriptive analysis
The characteristics of the patient population is shown in Table 1.
The majority of GIPAP patients were males (61%). About 85% of the
patients were treated for CML, 14% for GIST and 1% for other indica-
tions such as Philadelphia chromosome-positive acute lymphocyticleukemia (Ph+ ALL) and systemic mastocytosis. For the CML patients,
87% were in the chronic stage of the disease at diagnosis, 8% in the
accelerated stage and 5% in the blast stage. The mean and median age
of patients at enrollment into GIPAP were both 41 years, with a
median interquartile range of 22 years, and the mean duration from
disease diagnosis to enrollment in GIPAP was 10 months. The mean
and median duration of patient follow-up was 41 and 30 months
respectively with a median interquartile range of 51 months.
Our trend analysis of new patients ever enrolled in GIPAP in 93
countries showed a progressive increase in the number of new
patients enrolled in GIPAP from 2001 to 2007, a decline in 2008 and a
fairly constant number from 2009 to 2014 (Fig. 1). The total enrolled
patients increased from 12 in 2001 to 63,381 in 2014.3.1.1. Program outputs
GIPAP provided imatinib to more than 63,000 patients in 93 LMICs
between 2001 and 2014. Novartis donated about 72 million DDD and
66 million treatment days of imatinib to patients enrolled in GIPAP
during that time.3.1.2. Survival rates
Our survival analysis of all GIPAP patients enrolled from 2001 to
2014 shows a one-, three, five- and seven-year survival rate of 95%,
92%, 89% and 87%, respectively (Table 2).
Our disaggregated analysis showed that the short- (p < 0.0001)
and long-term (p < 0.0001) survival rates of CML patients were sig-
nificantly higher than those of non-CML patients. The one-, three-,
five- and seven-year survival rates for CML patients were 96%, 92%,
90% and 88% respectively compared to 95%, 90%, 86%, and 79% for
GIST patients (Table 2) (Fig. 2).
The disaggregated survival analysis of CML patients in different
phases of disease at diagnosis showed that those diagnosed in the
chronic phase had the best survival while those diagnosed in the blast
phase had the worst survival. The one-, three-, five- and seven-year
survival rates for chronic phase CML patients were 97%, 95%, 92% and
90% respectively compared to 89%, 83%, 80%, and 78% for accelerated
phase and 69%, 59%, 56% and 53% for blast phase (Table 3) (Fig. 3).
The proportional hazard regression showed that the risk of death in
non-CML patients was 24.6% higher than in CML patients (p < 0.0001),
after adjusting for sex, age at enrollment into GIPAP, time between
diagnosis and enrollment into GIPAP and year of enrollment.
Similarly, the result of the proportional hazard regression of
GIPAP CML patients showed that the risk of death in male patients
was seven percent higher than those of female patients (p = 0.0308),
after adjusting for CML phase at diagnosis, age at enrollment into
Fig. 1. Number of new patients enrolled in GIPAP 20012014.
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of enrollment (Table 4).
With each year increase in age at enrollment into GIPAP, the risk
of death in CML patients increases by 1.7%, holding other variables
constant (p < 0.0001). In addition, with each month increase in the
time between diagnosis and enrollment into GIPAP, the risk of death
in CML patients increases by 0.4%, holding other variables constant
(p < 0.0001). For each year increase in the year of enrollment, the
risk of death decreased by 3.5%, which means that those enrolled in
the later years of the program had a better survival rate. The risk of
death was 163% and 744% more likely in CML patients diagnosed at
the accelerated or blast phase, respectively, compared to those diag-
nosed at the chronic phase.Fig. 2. Disaggregated KaplanMeier Survival analysis of GIPAP patients, showThe estimated five-year potential number of CML patients saved by
GIPAP (see formula for calculation in the methods section) is 17,107.
3.1.3. Sensitivity analysis
Our sensitivity analysis based on the assumption that all the cases
lost to follow-up (12,679 patients) died at the time they were lost to
follow-up shows a one-, three-, five- and seven-year survival rate of
90%, 77%, 67%, and 57%, respectively (Table 5). The five-year potential
number of CML patients saved by GIPAP based on this assumption
will be 2757.
We also conducted sensitivity analyses without data from India and
China (both countries contributed about 50% of GIPAP patients), to see if
different results would be obtained. The analysis showed a one-, three-,ing survival rate of CML, GIST and other non-CML patients 20012014.
Fig. 3. Disaggregated KaplanMeier survival analysis of GIPAP CML patients, showing survival rate of CML patients in the chronic, accelerated and blast phases at diagnosis,
20012014.
Table 2




















One year 47,887 95.40% (95.2395.57) 41,853 95.50% (95.3295.68) 5808 95.25% (95.7394.77) 226 85.69% (89.3682.02)
Three year 28,270 91.88% (91.6392.13) 25,915 92.16% (91.9092.42) 2288 90.48% (91.3089.66) 70 72.09% (78.0966.09)
Five year 17,025 89.49% (89.1889.80) 15,988 89.99% (89.6790.31) 1021 85.59% (86.9084.28) 18 56.78% (68.4045.16)
Seven year 9068 87.13% (86.7487.52) 8667 87.79% (87.3988.19) 374 78.66% (80.8076.52)
a Other patients include: hypereosinophilic syndrome/chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, myelodysplastic syndromes/myeloproliferative dis-
order, systemic mastocytosis, and Ph positive ALL patients.
Table 3














One year 1038 68.81% (70.8166.81) 3142 89.46% (90.4088.51) 37,671 97.40% (97.5597.25)
Three year 455 58.99% (61.4256.56) 1713 82.53% (83.8281.24) 23,747 94.59% (94.8394.35)
Five year 235 56.05% (58.7453.37) 948 80.03% (81.4978.57) 14,797 92.44% (92.7592.13)
Seven year 123 53.14% (56.3049.98) 471 77.52% (79.3275.72) 8013 90.33% (90.7389.93)
AP: accelerated phase CML, BP: blast phase CML, chronic phase CML.
Table 4
Result of the proportional hazard regression of GIPAP CML patients 20012014.
Parameter Parameter estimate Standard error Hazard ratio (95% CI) p-value
Age at enrollment into program 0.01689 0.00104 1.017 (1.0191.015) <0.0001
Duration between diagnosis and enrollment into program (months) 0.00434 0.00040 1.004 (1.0051.004) <0.0001
Enrollment year 0.03529 0.00562 0.965 (0.9760.955) <0.0001
Sex (males vs females) 0.06732 0.03117 1.070 (1.1371.006) 0.0308
Disease phase at diagnosis (accelerated vs chronic) 0.96526 0.04329 2.625 (2.9582.412) <0.0001
Disease phase at diagnosis (blast vs chronic) 2.13341 0.04128 8.444 (9.1557.787) <0.0001
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Table 5
Sensitivity analysis based on assumption that all the cases lost to follow-up died at the time they were lost to follow-up.
Number at risk:
all patients










One year (12 months) 47,695 90.05% (89.8090.30) 41,682 90.15% (89.8990.41) 6013 89.52% (88.8590.19)
Three year (36 months) 28,168 76.90% (76.5277.28) 25,825 77.33% (76.9377.73) 2343 73.29% (72.0874.50)
Five year (60 months) 16,940 66.55% (66.0867.02) 15,910 67.35% (66.8667.84) 1030 58.21% (56.4859.94)
Seven year (84 months) 9025 57.44% (56.8858.00) 8626 58.48% (57.8959.07) 399 45.21% (43.0147.41)
6 C.A. Umeh et al. / EClinicalMedicine 19 (2020) 100257five-, and seven-year survival rates of 95%, 91%, 89%, and 87% respec-
tively which are similar to the survival rates in themain analysis.
4. Discussion
Our analysis showed a progressive linear increase in the number
of new patients enrolled in GIPAP from 2001 to 2007 with a dip in
2008 (Fig. 1). This dip in the linear trend of number of new enrollees
in 2008 was because Chinese GIPAP patients left GIPAP program in
2008 to join the China patient assistance program.
Our study also found that the three and five-year survival of CML
patients in GIPAP (92% and 90% respectively), unadjusted to patients’
prognosis at diagnosis, were similar to survival rates of CML patients
on imatinib in other settings [19,20]. This shows that despite the limi-
tations in providing cancer care in resource constrained settings in
LMICs, GIPAP patients do as well as patients in high income countries.
A 20052007 analysis of 13,568 GIPAP CML patients across 15 coun-
tries by Kanavos et al. [2] showed a minimum three years survival of
67% which is consistent with the survival rate in our sensitivity analy-
sis [2]. While we calculated the “survival rate” in our main analysis,
Kanavos et al. calculated the “minimum survival rate”, defined as the
proportion of patients who were still active in GIPAP after three
years. So patients who were lost to follow up, those who left GIPAP
and were receiving imatinib through other sources or those who
switched to other treatments options were regarded as “dead” for
the purposes of calculating the minimum survival rate. Conversely, to
calculate the survival rate, our event of interest was patients who
were confirmed as dead and we made adjustments in the Kaplan-
Meier survival analysis for those patients who had not died by the
time they left GIPAP for any reason.
The survival of GIST patients in our study, though less than that of
CML patients, was similar to the survival of patients with operable
GIST who received imatinib post-surgery [21]. However, the survival
was higher than the five year survival rate of 55% seen in patients diag-
nosed with advanced GIST (who are more similar to GIST patients in
GIPAP) in a previous study [22]. One reason for this disparity might be
due to the small sample size (147 patients) in the earlier study.
Furthermore, we observed that for each year increase in the year of
enrollment, the risk of death in CML patients decreased by 3.5% after
adjusting for CML phase at diagnosis, age at enrollment into GIPAP,
and time between diagnosis and enrollment into GIPAP, meaning that
those enrolled in the later years of the program had a better survival
rate. This improvement in survival might be due to physicians
improved experience with the use of imatinib and better monitoring
and supportive care of GIPAP patients. The roll out of GIPAP was
observed to have catalyzed the improvement of health care infrastruc-
ture and local resources needed to diagnose, monitor, and support
patients in the countries where GIPAP operated [1]. The important role
of The Max Foundation in monitoring and providing support to
patients, caregivers and physicians cannot be underestimated.
We found that the risk of death from CML was slightly higher in
males than females. This is consistent with other studies that have
identified the female gender as a favorable prognostic factor in CML
survival [2325]. The reason for the improved CML survival in
women is uncertain [26]. In our study, age at diagnosis, which could
affect survival, were similar for males (40 years) and females (41.5years). We do not have data on patient’s medication compliance and
whether it was different for males and females which if different
might explain the difference in survival. However, improved female
gender survival has also been reported for some other hematological
cancers such as acute myeloid leukemia [27] and acute lymphoblastic
leukemia [28,29].
Additionally, our study showed that younger patients survived
better than older ones. This is consistent with other studies that have
shown that younger CML patients have better prognosis than older
ones [30]. Old age was a major prognostic factor for CML survival
prior to the introduction of imatinib but now, age only has marginal
significance on survival and mainly with very old patients [31].
We estimated that the five-year potential number of CML patients
saved by GIPAP is 17,107. We believe the estimated number of
patients saved is a conservative estimate of the potential number of
lives saved by the GIPAP program for two reasons. First, the baseline
data of CML survival rate prior to the introduction of imatinib used in
our calculation was from a high-income country. We expect that the
baseline survival in the LMICs where GIPAP operates would be lower
than what we used in our calculation. Second, the patients in GIPAP
are poor patients who cannot pay for treatment privately and who do
not benefit from any reimbursement or insurance scheme [12]. These
are patients who without GIPAP might not be able to afford alterna-
tive cancer medications and so might have a far lower survival rate
without GIPAP.
Our sensitivity analyses without data from India and China (both
countries contributed about 50% of GIPAP patients), showed similar sur-
vival rates to the main analyses. This means that the survival of GIPAP
patients in China and India were similar to those in the other 91 coun-
tries. This makes us to believe that the survival rate of GIPAP patients in
this study can be generalized to other LMICs not included in the 93
countries if the programs are implemented in a similar fashion.
Although GIPAP has saved lives, one challenge of donation pro-
grams like GIPAP is program sustainability. Currently, it is recom-
mended that patients on imatinib should continue indefinitely and
this causes sustainability challenges [19]. To maintain sustainability,
Novartis in 2009 started the NOA in countries with a growing middle
class to provide imatinib at reduced prices to patients [1]. Under
NOA, Novartis shares the cost of imatinib with the government (as in
China), other payers, or individual patients (as in India and Philip-
pines). In 2017, Novartis and The Max Foundation initiated the transi-
tion of the GIPAP program to CMLPath to CareTM a model where
Novartis supports The Max Foundation with product donations and
funding, and The Max Foundation independently distributes dona-
tions to qualified institutions for approved patients under the
umbrella of its Max Access Solutions. CMLPath to Care continues to
provide access to imatinib to qualified patients in 65 countries and
additionally provides donations of nilotinib to qualifying patients in
39 countries as of December 2018. This new collaboration model has
allowed The Max Foundation to open the partnership to other manu-
facturers, makers of tyrosine kinase inhibitors (TKIs) and other oral
cancer medications. In 2017 Pfizer, Bristol-Myers Squibb, Takeda and
Incyte had established similar collaborations with The Max Founda-
tion under the umbrella of Max Access Solutions making available
eight compounds, three of which provide second and third line treat-
ments for CML, two provide first and second line for GIST, and others
C.A. Umeh et al. / EClinicalMedicine 19 (2020) 100257 7support patients with renal cell carcinoma, and AKL positive lung
cancer. As one of the benefits of the new model, at the end of 2017,
partner clinicians in 25 countries were able to prescribe and have
access to all TKIs approved elsewhere for the treatment of CML.
It is important to note that there are limitations in this study. First,
the data used for this analysis were routine program data that was
not collected for the purposes of program evaluation and so there are
gaps in the data such as absence of certain clinical and socio-demo-
graphic data of patients which limited the extent of the analysis. Sec-
ondly, there was no follow-up survival data for patients who left
GIPAP for any reason such as those who transferred to other patient
assistance programs. However, we dealt with this limitation by
modeling time contributed by patients that were lost to follow up as
censored data in the KaplanMeier model. Thirdly, in calculating the
number of lives saved through GIPAP we assumed that all the
patients receiving care through GIPAP would not have had access to
imatinib in the absence of the program. Although this assumption
might not be true for every single patient, we believe that for almost
all patients this assumption is true because patients were enrolled
into GIPAP only if they were not insured, not reimbursed, or could
not pay for the treatment privately and were in countries that have
minimal reimbursement capabilities.
Finally, we do not have information about the prognostic scores of
GIPAP patients, such as Sokal risk score, at diagnosis [32,33]. Without
adjusting for the prognosis of the patients at diagnosis, comparing
the survival of GIPAP patients with survival of patients from high
income countries becomes challenging. Considering that the median
age of GIPAP patients at initiation of treatment (41 years) was lower
than those seen in high income countries would place GIPAP patients
at a lower risk score with better prognosis. In the absence of a prog-
nostic score at diagnosis, the best conclusion we can make from our
study is that the survival of GIPAP patients is excellent, and unad-
justed for patients’ prognosis at time of diagnosis, compares favor-
ably to survival in high income countries.
5. Conclusions
Glivec International Patient Assistance Program (GIPAP) has
implemented a direct-to-patient drug donation model overseen by
patients’ oncologists. The program outputs are about 63,000 patients
in 93 countries who received over 71 million defined daily doses of
imatinib between 2001 and 2014. The impact of the program on sur-
vival showed a 5-year survival rate of 89 percent which is excellent,
and unadjusted for patients’ prognosis at time of diagnosis, compares
favorably to survival in high income countries despite the challenges
of delivering cancer care in LMICs.
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